Long-term results of Nivolumab + Cabozantinib in RCC

Published Date: 08 Mar 2023

The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

FDA approves Blenrep for relapsed or refractory multiple myeloma

2.

More Support for Early Detection; Cancer in Men Rising; Diet Drives Colon Cancer

3.

Survey: Record Numbers of US Adults Report Depression.

4.

Climate change is expected to increase the number of suicide deaths

5.

Charles III, King of Kings, is Cancerous.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot